No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
EHC240719C75000
- 12.50
- 0.000.00%
15min DelayTrading May 14 15:55 ET
0.00High0.00Low
0.00Open12.50Pre Close0 Volume131 Open Interest75.00Strike Price0.00Turnover0.00%IV3.05%PremiumJul 19, 2024Expiry Date9.91Intrinsic Value100Multiplier14DDays to Expiry2.59Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma8.41Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
Express News | Encompass Health Corp : Stephens Raises Target Price to $98 From $94
Here's Why Encompass Health (NYSE:EHC) Can Manage Its Debt Responsibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' When we think about how
Here's Why TimesSquare U.S. Mid Cap Growth Strategy Trimmed Encompass Health Corporation (EHC)
Encompass Health To Go Ex-Dividend On July 1st, 2024 With 0.15 USD Dividend Per Share
June 27th (Eastern Time) - $Encompass Health(EHC.US)$ is trading ex-dividend on July 1st, 2024.Shareholders of record on July 1st, 2024 will receive 0.15 USD dividend per share on July 15th, 2024. The
Encompass Health (EHC) Expands in Louisville With New Rehab Unit
Baptist Health Rehabilitation Hospital, a 40-bed Inpatient Rehabilitation Hospital, Now Open in Kentucky
Today, Baptist Health and Encompass Health (NYSE: EHC), the nation's largest owner and operator of inpatient rehabilitation hospitals, announce the...
Comments
Insiders selling shares below the current price could indicate their belief in the fairness of the lower price and skepticism about the higher valuation. However, the reasons for selling are varied and unknown. The level of insider ownership suggests some alignment with other shareholders.
Encompass Health Insider Lowered Holding By 26% During Last YearDespite solid earnings growth, the company's high P/E ratio is concerning given its lower forecast growth. Investors remain bullish, but the earnings growth may not sustain the share price. The high P/E ratio may not support the positive sentiment for long.
Encompass Health may be undervalued according to metrics, hinting a buying opportunity. The company's positive growth outlook isn't fully incorporated in its current share price. Considering management's track record is advised before investment.
Despite significant insider ownership possibly aligning company operations to all shareholders' interests, lack of insider buying over the past year is cautionary. Share sales at current trading prices could further induce wariness.
The company has shown similar rates of growth in EPS and share price, giving evidence that market perception of Encompass Health hasn't markedly changed. Considering the strong momentum in share price, it may be valuable to examine the stock further.
Read more